vimarsana.com

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Canada ,Australia ,South Korea ,United Kingdom ,Dan Paterson ,European Network Of Gynaecological Oncological Trial ,Chugai Pharmaceutical Co Ltd ,Company Annual Report On Form ,Exchange Commission ,Raf And Mek Program ,Genfleet Therapeutics Shanghai Inc ,Amgen ,Secura Bio Inc ,Drug Administration ,Linkedin ,Foundation Inc ,Verastem Oncology ,New Drug Application ,Breakthrough Therapy Designation ,Orphan Drug Designation ,European Network ,Gynaecological Oncological Trial ,Blinded Independent Central ,Low Grade Serous Ovarian Cancer ,Secura Bio ,Genfleet Therapeutics ,Annual Report ,

vimarsana.com © 2020. All Rights Reserved.